EA199700093A1 - ЛЕКАРСТВЕННЫЕ ФОРМЫ ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ, СОДЕРЖАЩИЕ β-ЛАКТАМНЫЙ АНТИБИОТИК - Google Patents

ЛЕКАРСТВЕННЫЕ ФОРМЫ ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ, СОДЕРЖАЩИЕ β-ЛАКТАМНЫЙ АНТИБИОТИК

Info

Publication number
EA199700093A1
EA199700093A1 EA199700093A EA199700093A EA199700093A1 EA 199700093 A1 EA199700093 A1 EA 199700093A1 EA 199700093 A EA199700093 A EA 199700093A EA 199700093 A EA199700093 A EA 199700093A EA 199700093 A1 EA199700093 A1 EA 199700093A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lactam antibiotic
dosage form
oral administration
administration containing
preparing
Prior art date
Application number
EA199700093A
Other languages
English (en)
Other versions
EA000361B1 (ru
Inventor
Геррит Ян Сейбрандс
Робертус Корнелис Ван Каутрик
Original Assignee
Яманучи Юроп Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Яманучи Юроп Б.В. filed Critical Яманучи Юроп Б.В.
Publication of EA199700093A1 publication Critical patent/EA199700093A1/ru
Publication of EA000361B1 publication Critical patent/EA000361B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Предлагается гранулят, содержащий по меньшей мере 50 мас.% водорастворимого β-лактамного антибиотика. Способ приготовления гранулята, содержащего подобный β-лактамный антибиотик, состоит в смачивании составляющих гранулят компонентов водным раствором, не содержащим существенных количеств связывающего агента для влажного гранулирования. Описаны лекарственные формы, содержащие указанный антибиотик в форме гранул, производное целлюлозы и разрыхлитель, которые быстро диспергируют при помещении в водную среду, а также способ приготовления подобных лекарственных форм.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199700093A 1995-02-08 1996-02-08 Способ приготовления гранулята, содержащего активный при пероральном введении бета-лактамный антибиотик EA000361B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200313 1995-02-08
PCT/EP1996/000547 WO1996024337A1 (en) 1995-02-08 1996-02-08 ORAL DOSAGE-FORMS CONTAINING A β-LACTAM ANTIBIOTIC

Publications (2)

Publication Number Publication Date
EA199700093A1 true EA199700093A1 (ru) 1998-02-26
EA000361B1 EA000361B1 (ru) 1999-06-24

Family

ID=8220003

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199700093A EA000361B1 (ru) 1995-02-08 1996-02-08 Способ приготовления гранулята, содержащего активный при пероральном введении бета-лактамный антибиотик
EA199900205A EA003736B1 (ru) 1995-02-08 1996-02-08 Лекарственная форма для перорального введения, содержащая бета-лактамный антибиотик

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA199900205A EA003736B1 (ru) 1995-02-08 1996-02-08 Лекарственная форма для перорального введения, содержащая бета-лактамный антибиотик

Country Status (19)

Country Link
US (1) US5948422A (ru)
EP (1) EP0801559B1 (ru)
CN (1) CN1125636C (ru)
AT (1) ATE216576T1 (ru)
AU (1) AU4789696A (ru)
BG (1) BG63528B1 (ru)
BR (1) BR9607189A (ru)
CZ (1) CZ293718B6 (ru)
DE (1) DE69620866T2 (ru)
DK (1) DK0801559T3 (ru)
EA (2) EA000361B1 (ru)
ES (1) ES2175073T3 (ru)
HU (1) HU227938B1 (ru)
MX (1) MX9706062A (ru)
NO (1) NO319993B1 (ru)
PL (1) PL186386B1 (ru)
PT (1) PT801559E (ru)
WO (1) WO1996024337A1 (ru)
ZA (1) ZA961018B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
US6242006B1 (en) 1996-07-16 2001-06-05 Gist-Brocades B.V. β-lactam granules free of organic solvents
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
CA2322315C (en) * 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
AU2001288102A1 (en) * 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
HUP0303178A3 (en) * 2001-02-05 2008-03-28 R P Scherer Technologies Methods and compositions for reducing the taste of pharmaceutically active agents
PL212421B1 (pl) * 2002-03-12 2012-09-28 Bristol Myers Squibb Co Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku
US8648065B2 (en) * 2002-10-02 2014-02-11 Meiji Seika Pharma Co., Ltd. Antibacterial medicinal composition of enhanced oral absorptivity
WO2004056363A2 (en) * 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
JP4926703B2 (ja) * 2003-07-03 2012-05-09 セルトリ・テクノロジーズ・エルエルシー セルトリ細胞および筋様細胞を含有する組成物、並びに細胞性移植における該組成物の使用
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
CA2626933C (en) * 2005-11-17 2015-12-29 Novartis Ag Pharmaceutical composition
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
CA2736531C (en) * 2008-09-17 2016-10-25 Niconovum Ab Process for preparing snuff composition
EP2367422A4 (en) * 2008-12-17 2013-01-09 Altheus Therapeutics Inc FORMULAS FOR LAVATION
WO2023204773A1 (en) * 2022-04-20 2023-10-26 Bilim Ilac Sanayii Ve Ticaret A.S. Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3344030A (en) * 1964-06-15 1967-09-26 American Home Prod Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
DE2251249A1 (de) * 1972-10-19 1974-05-02 Hoechst Ag Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
EP0281200B1 (en) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
EP0330284B1 (en) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
DE69525151T2 (de) * 1994-04-13 2002-08-14 Res Corp Technologies Inc Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin

Also Published As

Publication number Publication date
MX9706062A (es) 1997-10-31
HUP9801677A2 (hu) 1998-11-30
EA199900205A1 (ru) 2000-06-26
EP0801559A1 (en) 1997-10-22
PL321567A1 (en) 1997-12-08
DE69620866D1 (de) 2002-05-29
BG101822A (en) 1998-04-30
CN1125636C (zh) 2003-10-29
ZA961018B (en) 1997-08-08
CN1173816A (zh) 1998-02-18
EA000361B1 (ru) 1999-06-24
HU227938B1 (en) 2012-06-28
BR9607189A (pt) 1997-11-11
AU4789696A (en) 1996-08-27
EA003736B1 (ru) 2003-08-28
NO973646L (no) 1997-09-11
DE69620866T2 (de) 2003-02-27
CZ293718B6 (cs) 2004-07-14
EP0801559B1 (en) 2002-04-24
NO319993B1 (no) 2005-10-10
WO1996024337A1 (en) 1996-08-15
BG63528B1 (bg) 2002-04-30
CZ230297A3 (en) 1997-11-12
NO973646D0 (no) 1997-08-07
ES2175073T3 (es) 2002-11-16
US5948422A (en) 1999-09-07
PL186386B1 (pl) 2004-01-30
HUP9801677A3 (en) 1999-05-28
PT801559E (pt) 2002-09-30
ATE216576T1 (de) 2002-05-15
DK0801559T3 (da) 2002-06-17

Similar Documents

Publication Publication Date Title
EA199700093A1 (ru) ЛЕКАРСТВЕННЫЕ ФОРМЫ ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ, СОДЕРЖАЩИЕ β-ЛАКТАМНЫЙ АНТИБИОТИК
DE60019120D1 (de) Fenofibrat enthaltende pharmazeutische zusammensetzung und verfahren zu ihrer herstellung
PT781129E (pt) Preparacao farmaceutica contendo metformina e processo para a sua preparacao
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
EA200100354A1 (ru) Фармацевтическая композиция, содержащая энтакапон или нитекапон, а также поперечно-сшитое производное целлюлозы
FI940696A (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
DE59001005D1 (de) Hilfsmittelfreie riboflavingranulate.
PT91612A (pt) Process for the preparation pf 2-aza-4(alkoxycarbonyl> spiro<4,5> decan-3-on and of his own acid derivative 1-(aminomethyl)-cyclo-hexane-acetic
ES511097A0 (es) "procedimiento para la preparacion de derivados de oxindol".
WO1997010810A3 (en) Pharmaceutical granules
CA2224565A1 (en) Agent for combating parasites in farmed fish
FI885506A0 (fi) Farmaceutisk komposition och foerfarande foer framstaellning daerav.
RU97111095A (ru) Препарат для профилактики и лечения гельминтозов животных "альбамелин"
KR910700238A (ko) 치환된 아졸, 그의 제조방법, 그를 함유하는 제형 및 살진균제로서의 그의 용도
HU906387D0 (en) Herbicide preparatives containing new substituted sulphonyl-amidino-hydrazone derivatives as active substance and process for producing the active compounds
RU94036667A (ru) Биоэнергомодулятор
SE8302034D0 (sv) Dibenz(cd,f)indole derivatives, their preparation and pharmaceutical compositions containing them
FR2642754B1 (fr) Nouveaux derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): MD

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG TJ TM RU